This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Oral progesterone for the treatment of menopausal symptoms: clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014
One systematic review, 23 publications from randomized controlled trials, and two non-randomized studies were identified regarding the clinical efficacy of micronized progesterone or medroxyprogesterone, or the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone, for the management of menopausal symptoms.
Subject indexing assigned by CRD
Menopauses; Postmenopause; Progesterone
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published